Second-line Treatment of Primary Autoimmune Hemolytic Anemia

Recruiting now · Phase 3

Conditions studied: Primary Autoimmune Hemolytic Anemia

In brief

the cyclosporine showed efficacy in many immune cytopenic diseases in the light of numerous case reports and retrospective data. This study compares cyclosporin versus rituximab in steroid-refractory anemia.

Key facts

Study ID

NCT05057468

Run by

Assiut University

People needed

30

Starts

2021-10-20

Expected to finish

2026-11-30

Last updated by the study team

2025-03-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients aged more than 18 years old from any sex with a diagnosis of primary warm autoimmune hemolytic anemia (AIHA) based on the presence of hemolytic anemia and serological evidence of anti-erythrocyte antibodies, detectable by the direct antiglobulin test who have disease progression or failure after treatment with steroid therapy, or who are intolerant to treatment, or who refuse standard treatment.
• No evidence of a lymphoproliferative malignancy or other autoimmune-related underlying conditions.

You may not qualify if…

• any contraindications to the drugs of the study.
• any identified secondary cause of the AIHA.
• pregnant or lactating women.

Where it is running

• Assiut university hospital — Asyut, Asyut Governorate, Egypt (enrolling)
• Assiut university hospital — Asyut, Asyut Governorate, Egypt

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.